All News

2019

September

Media Release / Sep 06, 2019

Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer

Read More
Media Release / Sep 06, 2019

Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer

Read More
Media Release / Sep 05, 2019

Novartis study shows migraine support in the workplace can improve employee quality of life

Read More
Media Release / Sep 05, 2019

Novartis study shows migraine support in the workplace can improve employee quality of life

Read More
Media Release / Sep 03, 2019

Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine

Read More
Media Release / Sep 03, 2019

Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine

Read More
Media Release / Sep 02, 2019

Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings

Read More
Media Release / Sep 02, 2019

Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings

Read More
Media Release / Sep 01, 2019

Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint

Read More
Media Release / Sep 01, 2019

Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More